Glaxosmithkline

GlaxoSmithKline (GSK), a UK-based Pharmaceutical Preparation Manufacturing company, is committed to reducing its carbon emissions with ambitious targets. In 2024, GSK reported total Scope 1, 2, and 3 emissions of approximately 8.95 billion kg CO2e. This includes about 521 million kg CO2e from Scope 1 (direct emissions), approximately 44 million kg CO2e from market-based Scope 2 (indirect emissions from purchased energy), and roughly 8.39 billion kg CO2e from Scope 3 (value chain emissions). For 2025, GSK is projecting Scope 1 emissions of approximately 479 million kg CO2e and market-based Scope 2 emissions of approximately 7 million kg CO2e.

GSK has set Science Based Targets initiative (SBTi) approved targets. The company commits to achieving net-zero greenhouse gas emissions across its full value chain by 2045, from a 2020 baseline year. This includes a near-term target to reduce absolute Scope 1 and 2 GHG emissions by 80% by 2030, and to reduce absolute Scope 3 GHG emissions (from purchased goods and services, fuel and energy related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, use of sold products, and end-of-life treatment of sold products) by 80% within the same timeframe. Long-term, GSK aims to reduce absolute Scope 1 and 2 GHG emissions by 90% by 2045, and absolute Scope 3 GHG emissions (including capital goods and investments) by 90% by 2045, also from a 2020 base year.

Looking back, GSK reduced its Scope 1 and 2 carbon emissions by 15% in 2021 compared to 2020. The company previously aimed to reduce its carbon footprint by 25% across the business by 2020 from a 2010 baseline for Scope 1 and 2 emissions. Since its 2010 baseline, GSK has achieved a 25% reduction in annual carbon emissions from energy use (Scope 1 and 2) by 2017, saving a cumulative 1.9 million tonnes of CO2e. Additionally, GSK had a 2030 target, set against a 2016 baseline, to reduce operational carbon emissions (Scope 1 and 2) by 20% and value chain carbon emissions (Scope 3) by 25% per £ billion revenue. GSK has also committed to net-zero emissions across all operations (Scope 1 and 2) by 2030.